These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16906883)

  • 21. A mathematical model of tumour angiogenesis, regulated by vascular endothelial growth factor and the angiopoietins.
    Plank MJ; Sleeman BD; Jones PF
    J Theor Biol; 2004 Aug; 229(4):435-54. PubMed ID: 15246783
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dynamical model for assessment of anti-angiogenic therapy of cancer.
    Mukherjee A; Majumder D
    Mol Biosyst; 2010 Jun; 6(6):1047-55. PubMed ID: 20358121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular heterogeneity of tumor endothelium.
    Aird WC
    Cell Tissue Res; 2009 Jan; 335(1):271-81. PubMed ID: 18726119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endothelial cell heterogeneity.
    Aird WC
    Cold Spring Harb Perspect Med; 2012 Jan; 2(1):a006429. PubMed ID: 22315715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential therapeutic implications of intracrine angiogenesis.
    Re RN; Cook JL
    Med Hypotheses; 2007; 69(2):414-21. PubMed ID: 17320306
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour eradication by antiangiogenic therapy: analysis and extensions of the model by Hahnfeldt et al. (1999).
    d'Onofrio A; Gandolfi A
    Math Biosci; 2004 Oct; 191(2):159-84. PubMed ID: 15363652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
    Haspel HC; Scicli GM; McMahon G; Scicli AG
    Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?
    Rafii S; Lyden D; Benezra R; Hattori K; Heissig B
    Nat Rev Cancer; 2002 Nov; 2(11):826-35. PubMed ID: 12415253
    [No Abstract]   [Full Text] [Related]  

  • 29. Angiogenesis as a target for tumor treatment.
    Gastl G; Hermann T; Steurer M; Zmija J; Gunsilius E; Unger C; Kraft A
    Oncology; 1997; 54(3):177-84. PubMed ID: 9143396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Investigation of the Influence of Angiogenesis on Tumor Growth with the Use of a Mathematical Model].
    Kolobov AV; Kuznetsov MB
    Biofizika; 2015; 60(3):555-63. PubMed ID: 26349221
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A 2D mathematical model for tumor angiogenesis: The roles of certain cells in the extra cellular matrix.
    Pamuk S; Çay İ; Sazcı A
    Math Biosci; 2018 Dec; 306():32-48. PubMed ID: 30393207
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Engineered human tumor xenografts with functional human vascular networks.
    Alonso-Camino V; Santos-Valle P; Ispizua MC; Sanz L; Alvarez-Vallina L
    Microvasc Res; 2011 Jan; 81(1):18-25. PubMed ID: 20934439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting tumor vasculature: reality or a dream?
    Satchi-Fainaro R
    J Drug Target; 2002 Nov; 10(7):529-33. PubMed ID: 12683719
    [No Abstract]   [Full Text] [Related]  

  • 34. Continuous and discrete mathematical models of tumor-induced angiogenesis.
    Anderson AR; Chaplain MA
    Bull Math Biol; 1998 Sep; 60(5):857-99. PubMed ID: 9739618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of tumor-activated hepatic stellate cell as a target for the preclinical testing of anti-angiogenic drugs against hepatic tumor development.
    Olaso E; Vidal-Vanaclocha F
    Methods Mol Med; 2003; 85():79-86. PubMed ID: 12710199
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti-angiogenic therapies in cancer: achievements and open questions.
    Ruegg C; Mutter N
    Bull Cancer; 2007 Sep; 94(9):753-62. PubMed ID: 17878094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Regulation of tumor angiogenesis by fastatin, the fourth FAS1 domain of betaig-h3, via alphavbeta3 integrin.
    Nam JO; Jeong HW; Lee BH; Park RW; Kim IS
    Cancer Res; 2005 May; 65(10):4153-61. PubMed ID: 15899806
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of main pro- and anti-angiogenic factors in tumor angiogenesis.
    Huang Z; Bao SD
    World J Gastroenterol; 2004 Feb; 10(4):463-70. PubMed ID: 14966899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Significance of vascular endothelial growth factor--VEGF--in tumor angiogenesis. Therapeutic possibilities in solid tumors].
    Werther K; Nielsen HJ
    Ugeskr Laeger; 2000 Sep; 162(37):4916-20. PubMed ID: 11002739
    [No Abstract]   [Full Text] [Related]  

  • 40. Heterogeneity of angiogenesis and blood vessel maturation in human tumors: implications for antiangiogenic tumor therapies.
    Eberhard A; Kahlert S; Goede V; Hemmerlein B; Plate KH; Augustin HG
    Cancer Res; 2000 Mar; 60(5):1388-93. PubMed ID: 10728704
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.